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Abstract
Background
A discordant immune response (DIR) is a failure to satisfactorily increase CD4 counts on
ART despite successful virological control. Literature on the clinical effects of DIR has not
been systematically evaluated. We aimed to summarise the risk of mortality, AIDS and seri-
ous non-AIDS events associated with DIR with a systematic review.
Methods
The protocol is registered with the Centre for Review Dissemination, University of York
(registration number CRD42014010821). Included studies investigated the effect of DIR
on mortality, AIDS, or serious non-AIDS events in cohort studies or cohorts contained in
arms of randomised controlled trials for adults aged 16 years or older. DIR was classified
as a suboptimal CD4 count (as defined by the study) despite virological suppression fol-
lowing at least 6 months of ART. We systematically searched PubMed, Embase, and the
Cochrane Library to December 2015. Risk of bias was assessed using the Cochrane
tool for assessing risk of bias in cohort studies. Two authors applied inclusion criteria
and one author extracted data. Risk ratios were calculated for each clinical outcome
reported.
Results
Of 20 studies that met the inclusion criteria, 14 different definitions of DIR were used. Risk
ratios for mortality in patients with and without DIR ranged between 1.00 (95% CI 0.26 to
3.92) and 4.29 (95% CI 1.96 to 9.38) with the majority of studies reporting a 2 to 3 fold
increase in risk.
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Conclusions
DIR is associated with a marked increase in mortality in most studies but definitions vary
widely. We propose a standardised definition to aid the development of management
options for DIR.
Background
Antiretroviral therapy (ART) substantially reduces the incidence of acquired immunodefi-
ciency syndrome (AIDS) and mortality, with increased CD4 cell count significantly and inde-
pendently associated with improved prognosis [1–4]. Some patients do not achieve CD4 cell
count reconstitution with ART, despite achieving suppression of HIV viral load in the blood
[5]. This paradoxical response is referred to by various terms in the literature including discor-
dant immune response (DIR), poor or suboptimal immune reconstitution, incomplete immune
recovery or restoration and immunological non-response. Here, we use the term discordant
immune response as it was the term most frequently used by the included studies [6–10].
There is currently no agreed case definition for DIR.
Over 13 million people worldwide are on ART, with a further 22 million eligible [11].
Understanding limitations to its success will be critical in improving individual responses to
treatment and regimen durability. The 2013 World Health Organization (WHO) consoli-
dated guidelines on treatment of HIV now favour use of HIV viral load monitoring for rou-
tine identification of ART treatment failure [12], but CD4 cell counts for patients established
on ART remain an important clinical and prognostic tool and are essential for identifying
DIR [13, 14].
Much research has focused on CD4 reconstitution on ART, but the mechanisms promoting
DIR are not well understood. Damage to CD4 T cells begins prior to ART initiation due to
direct effects of the HIV virus on thymic tissue and depletion of progenitor cells[15]. Thymic
output may be disproportionally affected in patients who start ART at lower CD4 counts lead-
ing to under-reconstitution of naïve CD4 T cells[16, 17]. Lymph node fibrosis is also major fea-
ture and correlates with duration of HIV infection prior to ART initiation [18, 19]. Untreated
HIV infection leads to a significant activation of the immune system [20], resulting in a cycle
of systemic inflammation, persistent T cell activation, exhaustion and death [21–23]. The
extent of immune activation at the time of ART initiation is associated with the development
of DIR [4, 24] and predicts mortality on ART [25]. HIV induced T cell dysfunction and inflam-
mation are closely related to serious non-AIDS events [20, 26]. Persistent immune activation is
often detected despite virologically suppressive ART [27] and can be driven by microbial trans-
location[28], low level persistent HIV viral replication[29], and latent co-infections such as
CMV [30, 31] and tuberculosis [32, 33]. Innate immune cells including monocytes, macro-
phages and NK cells also perpetuate immune activation, but this axis is more specifically driven
microbial translocation, LPS antigenaemia and circulating soluble CD14 and does not neces-
sarily correlate with T cell activation [34–37].
Non-systematic reviews have previously been carried out into aetiologies, prevalence and
potential management of DIR [38–44]. However, the literature is heterogeneous and in order
to better understand the burden of DIR, we sought to systematically characterise the risk of
mortality, AIDS and serious non-AIDS events associated with DIR across the published
literature.
Outcomes in Discordant Immune Response
PLOS ONE | DOI:10.1371/journal.pone.0156099 June 10, 2016 2 / 21
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Methods
The study protocol was registered with the Centre for Review Dissemination, University of
York (registration number CRD42014010821). The systematic review has been reported in
accordance with the PRISMA guidelines [45] (See S1 Checklist).
Eligibility criteria
Participants. Participants were aged 16 years or older and no restrictions were placed on
language or geographical region.
Participants with DIR were defined as patients who had been taking ART for at least 6
months and who were virologically suppressed, but had a suboptimal CD4 count according to
study definitions. Studies defined a suboptimal CD4 count in terms of either a failure to achieve
a pre-specified rise in CD4 count or a pre-specified absolute CD4 value at a specific time point
following ART initiation. Virological suppression was defined as at least one single HIV viral
load measurement of below 1000 copies/ml after at least 6 months of ART. Studies that did not
report on the virological status of the cohort were not included.
Outcomes. Studies were included if they estimated the risk of mortality, AIDS or serious
non-AIDS events associated with DIR. Studies were included if death was verified by clinician
review, tracing or verbal autopsy. AIDS was defined as any illness that met criteria for a WHO
stage 4 condition [46]. Serious non-AIDS events were defined as illnesses not included in the
WHO Clinical Staging System, and which were non-communicable. These include non-com-
municable cardiovascular, liver, renal and bone diseases as well as non-AIDS related malignan-
cies. Studies reporting AIDS and serious non-AIDS events were deemed to meet our inclusion
criteria if the events had been verified at least by clinician review of participant records.
Study design. Studies were eligible for inclusion if they were cohort studies or randomised
controlled trials (RCTs). We excluded editorials and comments, case reports and case series,
qualitative studies, mathematical modelling studies, and economic analyses.
Information sources and search methods
We searched the following databases: Cochrane Central Register of Controlled Trials (CEN-
TRAL, in the Cochrane Library issue 1, 2016); MEDLINE (PubMed; 1966 to 31st December
2015); EMBASE (OVID; 1980 to 31st Decemeber 2015). Table 1 shows the search strategy used
in Medline (PubMed); this was modified for the other electronic databases.
Study Selection and Data Collection
Titles of studies identified from the database search were independently reviewed by two
authors (CK and KG) and were excluded if the study was unrelated to the review subject.
Remaining studies underwent independent abstract review and then full text review by the
same two reviewers. Pre-piloted data extraction forms were independently applied to all studies
that underwent full text review. Where disagreement occurred, a consensus was reached by dis-
cussion or a third reviewer was consulted (PM). Where outcome data were not reported, the
lead study author was contacted.
Risk of bias
Risk of bias assessment was based on the Cochrane Tool for Assessing Risk of Bias in Cohort
Studies [47]. The Cochrane Tool for Assessing Risk of Bias in Randomised Control Trials was
not used because no RCTs targeting DIR were identified that met the inclusion criteria.
Outcomes in Discordant Immune Response
PLOS ONE | DOI:10.1371/journal.pone.0156099 June 10, 2016 3 / 21
Potential sources of bias were assessed in three domains: ‘study design’; ‘comparability’; and
‘assessment of outcomes’.
The study design domain assessed whether participants were selected to be representative of
adults on ART, and if there were clear selection criteria for those with and without DIR. Studies
with more stringent selection criteria based on, for example, frequency of CD4 and viral load
monitoring or attendance at routine clinics prior to enrolment, were deemed to be at a high
risk of bias because they might exclude populations at higher risk of DIR and therefore were
not representative of the entire population of patients with DIR. The comparability domain
assessed if patients with and without DIR were managed according to the same standardised
protocol and if outcomes were reported after appropriate adjustment for potential confounding
variables. For the assessment of outcomes domain, outcomes had to be measured using clini-
cian review, case note review, verbal autopsy or autopsy. Studies that did not report at least one
of these methods were deemed high risk of bias for this category. The minimum acceptable fol-
low-up period was one year as this is the highest risk period for adverse clinical outcomes post
ART initiation [48].
An overall risk of bias assessment was made for each individual domain. A domain would
be classified as high risk of bias if any one question within it failed the specified criteria. Where
insufficient information had been reported in a study to make a judgement on the risk of bias,
that question was recorded as unclear. ‘Unclear’ and ‘high risk’ categories were then combined
for the purposes of analysis [49].
Summary measures and synthesis of results
For each study, the proportion of participants with and without DIR who died, and/or experi-
enced an AIDS-related, or serious non-AIDS-related event were estimated. Risk ratios and 95%
confidence were extracted from the manuscript or calculated. A meta-analysis with pooled
effect estimates were planned but could not be carried out due to considerable variation in both
DIR definition and length of follow-up.
Table 1. Search strategy.
Search
#16 Search (#5) AND #15
#15 Search (((((((((#6) OR #7) OR #8) OR #9) OR #10) OR #11) OR #12) OR #13) OR #14) OR #15
Field: Title/Abstract
#14 Search incomplete CD4* response Field: Title/Abstract
#13 Search discordant* Field:Title/Abstract
#12 Search immunovirological discordance* Field: Title/Abstract
#11 Search low CD4* Field: Title/Abstract
#10 Search insufﬁcient CD4* Field: Title/Abstract
#9 Search suboptimal CD4* Field: Title/Abstract
#8 Search low responder* Field: Title/Abstract
#7 Search suboptimal immune response*[Title/Abstract]
#6 Search suboptimal immune reconstitution [Title/Abstract]
#5 Search (#1) AND #4
#4 Search (#2) OR #3
#3 Search (antiretroviral[Title/Abstract]) OR ART[Title/Abstract]
#2 Search antiretroviral therapy [Title/Abstract]
#1 Search "HIV Infections"[Mesh]
doi:10.1371/journal.pone.0156099.t001
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Results
Study selection
2782 study titles were identified by the search. Twenty studies met inclusion criteria for full-
text review (Fig 1). The two most common reasons for exclusion were that the study did not
report a clinical outcome (36%) and the cohort was not virally suppressed (23%). Authors
from the study by Young et al were contacted to clarify if participants had been on ART for at
least 6 months but the data were no longer available and so the study was excluded.
Study characteristics
Twenty studies were included [4, 6–9, 50–64], all of which were cohort studies. For three studies,
the cohort was established de novo to investigate the effects of DIR on clinical outcomes [4, 51, 58,
64]. One study analysed DIR and outcomes in the control arm of an RCT assessing ART regimes
for individuals initiating ART [50]. The remaining 14 studies conducted secondary analysis of exist-
ing datasets comprising of national or international cohorts of HIV infected patients who had data
collected prospectively and systematically during routine clinical care [6–9, 52–57, 59–63].
Seventeen studies recruited participants from HIV care clinics. Five studies included partici-
pants from resource-limited countries [4, 9, 58, 63, 64]: three from countries with a generalised
HIV epidemic (Uganda, South Africa) [4, 58, 64]; one from Senegal [63]; and one from an
international collaboration of both low-, and middle-income countries [9]. Participants were
ART-naïve in 16 studies [4, 6–9, 50, 51, 53, 55–60, 63, 64] whereas four studies included
patients who were ART naïve and experienced [52, 54, 61, 62].
For included studies, the median proportion of male participants ranged from 31%– 100%
and median age ranged from range 34 to 43 years (Table 2). Median CD4 cell count at ART ini-
tiation was reported for 15 studies and ranged from 80–221 cells/mm3. Median HIV viral load
at ART initiation was reported for 10 studies and ranged from 4.5 log10−5.1 log10 copies/ml.
The threshold for defining virological suppression ranged from<50 copies/ml to<1000 copies
per ml. Participant follow-up ranged from 1 to 7 years.
Risk of bias
Two (10%) studies had a high risk of bias in study design; 6 (30%) in comparability; and 11
(55%) in assessment of outcomes (Table 3).
Fig 1. Flow of paper selection from those identified following literature search through to inclusion.
doi:10.1371/journal.pone.0156099.g001
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Table 2. Description of 20 included studies.
Study author Study
design
Year of
publication
Median
Duration
of
follow-
up
Country Setting Relevant
Outcomes
examined
ART
naïve?
%
Male
Median
age
(years)
Median
CD4
(cells/
uL) at
ART
initiation
Median
HIV VL
(log10
copies/
mL) at
ART
initiation
BAKER [50] Control arm
of ART RCT
2008 5 years USA Community,
80 sites
Predictors
and clinical
outcomes of
patients with
DIR
Yes 80 39 221 5.0
BATISTA [63] Established
HIV cohort2
2015 7 years Senegal HIV care
clinic
Frequency
and risk
factors for
DIR, and
incidence of
OI and death
Yes 35 40 Not
reported
Not
reported
DRONDA [51] Prospective
cohort
study1
2002 3 years Spain HIV care
clinic
Immunologic
and clinical
outcomes of
patients with
DIR
Yes 74 36 196 5.0
ENGSIG [52] Established
HIV cohort2
2010 4.7 years Denmark HIV care
clinics, 8
sites
Predictors
and mortality
of patients
with DIR
No 78 435 Not
reported
Not
reported
FALSTER
[53]
Established
HIV cohort2
2008 5.4 years Australia HIV care
clinics,
number of
sites not
reported
Prevalence
of DIR, and
and clinical
outcomes
Yes 935 Not
reported
Not
reported
Not
reported
GILSON [6] Established
HIV cohort2
2010 3 years UK HIV care
clinics, 10
sites
Predictors
and clinical
outcomes
Yes 75 37 170 5
Study author Study
design
Year of
publication
Median
Duration
of
follow-
up
Country Setting Relevant
Outcomes
examined
ART
naïve?
%
Male
Median
age
(years)
Median
CD4
(cells/
uL) at
ART
initiation
Median
HIV VL
(log10
copies/
mL) at
ART
initiation
GRABAR [54] Established
HIV cohort2
2000 18
months
France HIV care
clinics, 68
sites
Clinical
outcomes of
patients with
DIR
No 79 37 150 4.54
GUTERRIEZ
[55]
Established
HIV cohort2
2008 2.3 years Spain HIV care
clinics, 10
sites
Predictors
and clinical
outcomes of
patients with
DIR
Yes 75 37 160 5.0
HUNT [4] Prospective
cohort
study1
2011 2 years Uganda HIV care
clinic
Mortality
according to
CD4
account3
Yes 30 34 135 5.1
KAUFMANN
[56]
Established
HIV cohort2
2004 5 years Switzerland HIV care
clinics,
number of
sites not
reported
Predictors
and clinical
outcomes of
patients with
DIR
Yes 74 38 180 4.9
(Continued)
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Table 2. (Continued)
LOUTFY [57] Established
HIV cohort2
2010 2.7 years Canada HIV care
clinics, 9
sites
Clinical
outcomes of
patients with
DIR
Yes 83 40 180 5.0
MOORE [7] Established
HIV cohort2
2005 3.7 years Canada HIV care
clinic
Predictors
and mortality
in patients
with DIR
Yes 775 39 199 Not
reported
NAKANJAKO
[58]
Prospective
cohort
study1
2008 1.8 years Uganda HIV care
clinic
Prevalence
of DIR and
clinical
outcomes
Yes 31 38 98 Not
reported
Study author Study
design
Year of
publication
Median
Duration
of
follow-
up
Country Setting Relevant
Outcomes
examined
ART
naïve?
%
Male
Median
age
(years)
Median
CD4
(cells/
uL) at
ART
initiation
Median
HIV VL
(log10
copies/
mL) at
ART
initiation
NICASTRI
[61]
Established
HIV cohort2
2005 3.7 years Italy Hospital, 63
sites
Immunologic
and clinical
outcomes
No 72 35 185 4.78
PACHECO
[59]
Established
HIV cohort2
2009 6 years Spain Hospital, 10
sites
CD4 count
recovery,
predictors
and mortality
in patients
with DIR
Yes 325 Not
reported
Not
reported
Not
reported
TAKUVA [64] Prospective
cohort
study1
2014 2 years South
Africa
HIV care
clinic, 1 site
Mortality and
AIDS
associated
with DIR
Yes 36 39 80 Not
reported
TAN [8] Established
HIV cohort2
2008 3.2 year USA HIV care
clinic
Clinical
outcomes in
patients with
DIR
Yes 76 38 213 5.4
TAIWO [62] Established
HIV cohort2
2009 Not
reported
USA HIV care
clinics, 4
sites
Clinical
outcomes in
patients with
DIR
No 100 42 Not
reported
Not
reported
TUBOI [9] Established
HIV cohort2
2010 1 year Multi-
centre4
HIV care
clinics, 31
centres
Mortality in
patients with
DIR
Yes 39 34 100 Not
reported
ZOUFALY
[10]
Established
HIV cohort2
2010 3.8 years Germany HIV care
clinics, 11
sitess
Predictors
and clinical
outcomes in
patients with
DIR
Yes 77 39 80 Not
reported
ART = anti-retroviral therapy, cART = combination anti-retroviral therapy, DIR = discordant immune response, VL = Viral load, PI = Protease inhibitor,
NRTI = nucleoside reverse transcriptase inhibitor, DDI = didanosine, TDF = tenofovir, LMIC- = Low and middle income countries.
1 Patients are enrolled speciﬁcally for the aims of the current study.
2 Retrospective analysis of prospectively collected data.
3Analysis of clinical outcomes in DIR is a secondary analysis in this study.
4Includes countries from Africa, South America and Asia.
5Not reported for entire cohort therefore median value from optimal immune response group reported.
doi:10.1371/journal.pone.0156099.t002
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For the study design domain, Engsig et al required a viral load of<50 copies /ml for more
than three consecutive years before the start of the DIR observation period [52], and Kaufmann
et al required a viral load of<1000 copies/mL during the entire 5-year observation period [56].
The frequency of visits these criteria would require may have excluded patients at higher risk
of DIR. All studies detailed clear selection criteria for participants with and without DIR.
For the comparability domain, participants with and without DIR were managed according
to the same treatment protocols for all studies but 6 studies did not appropriately evaluate the
effects of confounders on outcomes [50–53, 56, 58].
For the assessment of outcomes domain, two studies gave no information on how deaths
[56, 57] or AIDS events [57] were ascertained. Eleven studies did not describe how missing
data were handled [6, 50, 52, 53, 56–60, 62, 63].
Definition of DIR
Definitions of DIR varied significantly and were classified into two categories: a failure to
achieve a prespecified absolute CD4 count at a predefined time point; or a failure to achieve a
prespecified rise in CD4 count from baseline at a predefined time point (Table 4). Five studies
explored several potential definitions of DIR [6, 10, 57, 58, 64].
Eleven studies defined DIR based on a failure to achieve a rise in CD4 from ART initiation
[6–9, 50, 51, 54, 55, 58, 61, 63] and used CD4 count thresholds of a failure to achieve a rise of at
least 50 cells/ mm3 at 6 months [7–9, 63]; at least 100 cells/ mm3 at 12 months [51, 58]; at least
50 cells/ mm3 at 12 months [54, 55]; at least 50 cells/ mm3 at 8 months [50]; and at least 100
cells/ mm3 at 8 months [6].
Nine studies defined DIR based on a failure to achieve an absolute CD4 count at a prede-
fined time point [4, 10, 52, 53, 56, 57, 59, 62, 64] and used the following CD4 count thresholds:
200 cells/ mm3 at 6 months[64], 200 cells/ mm3 at 12 months [10, 57]; of 350 cells/ mm3 at 9
months [53]; of 250 cells/ mm3 at 22 months [59]; 200 cells/ mm3 at 36 months [52]; and
500cells/ mm3 at 60 months [56]. Hunt and colleagues described mortality according to tertiles
of CD4 counts in patients with viral suppression rather than use a single definition for DIR [4]
so we compared mortality in the highest tertile (>177 cells/mm3) to the lowest tertile (<95
cells/mm3), using the lowest tertile of CD4 counts as the ‘DIR group’.
HIV VL cut offs used by studies to define virological suppression were as follows: 50 copies/
ml (seven studies) [6, 10, 51, 52, 57, 62, 63]; 400 copies/ml (four studies) [50, 53, 58, 64]; 500
copies/ml (four studies) [7, 9, 55, 61]; and 1000 copies/ml (four studies) [4, 54, 56, 59]. One
study only reported using an ‘undetectable’ VL [8]. The time period for the definition of viro-
logical suppression was as follows: a one off cut off point between 6 months to a year post ART
(eight studies) [7–9, 50, 54, 61, 63, 64]; two measurements over one year (two studies) [6, 53];
quarterly measurements for 2 years (two studies) [51, 58, 59], and quarterly measurements
throughout the period of follow-up (seven studies) [4, 10, 55–57, 62, 65].
Effect of DIR on risk of mortality
The risk of mortality ranged between 3% to 23% for patients with DIR and 1% to 7% for
patients without DIR, over a median follow-up time of 2 years and 3.7 years respectively. Ten
studies estimated the effect of DIR on mortality [4, 6–9, 50, 52, 55, 56, 59] (Table 4). Risk ratios
ranged between 1.00 (95% CI 0.26–3.92) and 4.29 (95% CI 1.96–9.38). Six of nine studies
showed a significantly higher risk of mortality in participants with DIR compared to partici-
pants without DIR [6–9, 55, 56] (Fig 2A). Two studies reported on the absolute risk of mortal-
ity in participants with DIR in resource-limited settings [4, 9], with Tuboi et al finding DIR to
be significantly associated with an increased risk of death.
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Ten studies reported the incidence of mortality in participants with DIR (Table 5). Six
found the incidence of mortality to be significantly higher in participants with DIR compared
to participants without DIR [6–9, 55, 64]. Incidence rate ratios ranged from 1.78 (95% CI 1.09–
2.90) to 4.01 (95% CI 1.62–9.94). One study from a sub-Saharan Africa setting (South Africa)
reported rates of mortality and found an IRR of 1.78 (1.09–2.90). No differences in risk of mor-
tality were found according to DIR defined as absolute or rise, CD4 count cut off or time period
post ART initiation.
Effect of DIR on risk of AIDS and serious non-AIDS events
Six studies reported AIDS events [6, 8, 10, 50, 55, 58]. The risk ratio for associations between
DIR and AIDS events ranged from 0.96 (95% CI 0.53–1.76) to 2.70 (95% CI 1.29–5.66) (Fig
2B). One of these reported AIDS events in a low resource setting (Uganda) with a risk ratio of
1.94 (0.86–4.35). Five studies reported combined AIDS events or mortality [51, 53, 54, 57, 61]
and risk ratios ranged from 0.86 (95% CI 0.41–1.80) to 2.06 (95% CI 0.89–4.79) (Fig 2C). One
study from a low resource setting (Senegal) reported an incidence rate ratio of 1.21 (0.85–1.72).
Four studies detailed AIDS events. The most commonly reported pathologies were oesopha-
geal candidiasis, tuberculosis, AIDS related cancers, pneumocystis jirovecii and bacterial pneu-
monia [50, 55, 58, 60]. Only Baker et al included serious non-AIDS events [50], reporting
events in eight of 143 patients (5.6%) with DIR compared to 31 of 671 patients (4.6%) without.
Discussion
The main finding of this review was that we found definitions used to categorise DIR varied
widely, with 14 different definitions used in the 20 included studies. This greatly limits the abil-
ity to draw conclusions about clinical burden in this patient cohort. This paper has synthesised
existing data and suggested the definition for DIR to be a rise of less than 50 cells/uL at 6
months following ART initiation in those who have achieved virological suppression but with
a CD4 count of less than 350 cells/uL. This provides a starting point for the development of
consensus within the field. For the majority of included studies, mortality in patients with DIR
was two to three times higher than in those with a satisfactory immune response. To our
knowledge, this is the first review to systematically examine the fate of adults with DIR. Two
further important gaps in the literature were identified: the large majority of current data
Fig 2. Forest plot showing risk of clinical outcomes for patients with DIR across those studies
reporting each outcome: A) Mortality B) AIDS events C) Combinedmortality and AIDS events.
doi:10.1371/journal.pone.0156099.g002
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reports on cohorts from high income countries; and only one study reported on the burden of
serious non-AIDS events. Both the clinical burden of DIR in low income settings and the global
burden of serious non-AIDS events remain unclear. It is not possible to draw comparisons
between the risks associated with DIR in low resource to high resource settings with the current
literature.
Although pooled meta-analysis was inhibited by heterogeneity in length of follow-up, mor-
tality rates remain substantially and significantly elevated in patients with DIR in studies that
reported rates adjusted for time. The relationship between DIR and AIDS is less clear and may
be complicated by challenges in diagnosing or reporting AIDS conditions. Alternatively, other
conditions such as serious non-AIDS events may be contributing to mortality and this warrants
further investigation.
The scope of this review was also limited by heterogeneity in DIR definitions. In order to
address this, we advocate the use of a standard definition. To define DIR based on a failure to
achieve a rise in CD4 from baseline is more reflective of the amount of time spent at a lower
CD4 count, which is an important predictor of poor outcomes [14]. In contrast, an absolute
CD4 count at a given time point may only tell us about that point in time, when other factors
such as co-existing infections may be affecting the CD4 count. The expected rate of CD4 recon-
stitution following ART initiation is 20 to 30 cells per month in the first 6 months and then 5
to 10 cells per month between 6 months and 24 months [66, 67]. Therefore, when choosing a
time point to measure DIR, we believe that 6 months after ART initiation is logical.
Many studies included in this review based their definition of DIR on a failure to achieve a
rise of 50 cells/uL at 6 months post ART initiation. Whilst this is a relatively strict CD4 cut off,
these studies still reported a high proportion of virologically-suppressed patients with DIR. We
would therefore recommend defining DIR as a rise of less than 50 cells/uL at 6 months follow-
ing ART initiation in patients who have achieved virological suppression. This definition has
the benefit of identifying a high risk group of patients early on in the course of their ART man-
agement to allow for increased benefit of any potential intervention. It is logical that this defini-
tion would only apply to those commencing ART with a CD4<350 cells/uL so as not to over
diagnose DIR in a population starting with higher CD4 counts. The heterogeneity in defini-
tions for DIR and outcome measures means that it is not currently possible to compare the util-
ity of definitions to predict clinical outcomes. We recommend further studies to clinically
validate a standardised definition.
This review should be interpreted in the light of several limitations. Firstly, the majority of
studies were carried out using data collected from ongoing multicentre cohort studies, meaning
cohorts are likely to be highly selected in terms of laboratory monitoring and attending follow-
up visits. This limits the generalizability of the studies, and may mean that the risk of adverse
clinical outcomes in individuals with DIR could be underestimated. Secondly, the HIV viral
load limit defining virological suppression varied across studies. However, it remains unclear
whether differences in viral load below 1000 copies/ml are biologically significant [68]. Lastly,
individual studies did not distinguish between early mortality in patients starting ART with
advanced immunosuppression and long term mortality due to poor immune reconstitution.
This could be addressed in future studies.
There are currently no effective therapeutic options to reduce the excess mortality associ-
ated with DIR and further research is required. One approach under evaluation is to target
underlying drivers of immune activation and inflammation. The addition of raltegravir to stan-
dard two class regimes at ART initiation has the aim of decreasing viral set point but as yet
only two small studies have shown any effect on immune responses [69, 70]. Similarly a recent
trial with valganciclovir to tackle ongoing CMV replication failed to show any improvement in
CD4 count [71]. Although probiotics can improve the systemic pro-inflammatory profile,
Outcomes in Discordant Immune Response
PLOS ONE | DOI:10.1371/journal.pone.0156099 June 10, 2016 14 / 21
there is no evidence that this can improve CD4 counts [72]. To address generalised inflamma-
tion, anti-inflammatory agents such as statins and anti-rheumatic agents have been tested [73,
74]. Whilst statins reduced peripheral immune cell activation, there is no evidence that they
can improve CD4 T cell count. Studies investigating the role of quinolones in reducing HIV
related immune activation have shown only small decreases in inflammatory markers [75].
Immunomodulatoy agents such as IL-2 have shown limited success [76, 77] and current focus
is being placed on IL-7 therapy [78, 79] with several ongoing trials in progress. Lastly, agents
aimed at stimulating thymic output have also been tested in early studies [80, 81].
Practical management options may be more accessible in the short term. Standardised
guidelines could recommend continuation of prophylactic therapies such as co-trimoxazole
and isoniazid for patients with DIR, or could prompt investigation for subclinical opportunistic
infections such as tuberculosis and CMV. Although prevention of DIR through early diagnosis
of HIV infection and prompt treatment with ART is likely the most effective intervention [82–
85], a large proportion of patients worldwide continue to present with advanced HIV infection
[86, 87].
This systematic review highlights that a wide range of definitions have been used to charac-
terise clinical outcomes in patients with DIR. These patients are at an increased risk of mortal-
ity and are in need of special attention, including integration into HIV clinical trials. We have
suggested a definition for DIR based on the limited available data in order to help begin the
process of arriving at a consensus definition that could be used to guide clinical care and in
future research. We recommend that further studies validate this definition for DIR to aid the
development of consensus guidelines.
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